Hikma’s Board has noted the significant amount of interest shown in its Injectables business by third parties, demonstrating both the attractiveness of the global injectables market and the strength of Hikma’s business. 

The Board believes that Hikma is uniquely positioned to create significant further value by retaining this business and leveraging its high-quality manufacturing facilities, broad product portfolio, attractive R&D pipeline and global distribution platform. Hikma’s Injectables business is performing very well and the Board is confident in management’s ability to continue to execute its Injectables growth strategy.

Said Darwazah, CEO of Hikma, said "After a thorough review of strategic options for the Injectables business, we are confident that retaining and continuing to invest in this business is the best option for shareholders.  Injectables offers excellent long-term growth prospects and will remain an integral part of our overall growth strategy.  By retaining the business, we will also continue to benefit from our diversified business model, which combines our global Injectables business with our oral generic business in the US and our extensive presence and experience in the Middle East and North Africa.”